8 December 2016Americas

CRISPR dispute likely to continue in federal courts

Following the CRISPR/Cas9 patent hearing on December 6 between The Broad Institute and University of California, Berkeley (UCB), it is very unlikely that the case will end at the US Patent and Trademark Office (USPTO), according to one lawyer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 February 2026   The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.
Americas
19 February 2026   An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.
Americas
19 February 2026   The genetic testing firm claims that a former oncology specialist stole hundreds of confidential files in the dead of night, days before moving to a competitor.